MetaVia to Participate in Life Sciences Investor Forum
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2026
0mins
Should l Buy MTVA?
Source: PRnewswire
- Executive Participation: MetaVia's CEO Hyung Heon Kim will participate in the Life Sciences Virtual Investor Forum on March 12, 2026, showcasing the company's innovative pipeline in obesity and metabolic therapies, which is expected to attract investor interest and enhance company visibility.
- Real-Time Interaction: The event will feature a live Q&A session, allowing investors to directly engage with management, thereby enhancing investor participation and fostering interaction between the company and potential investors, which may aid future fundraising efforts.
- Clinical Trial Progress: MetaVia's DA-1726 has demonstrated best-in-class potential for weight loss in a Phase 1 multiple ascending dose trial, indicating promising prospects for weight control and glucose management, potentially providing a competitive edge in the market.
- New Drug Development Results: Vanoglipel has shown positive effects on liver inflammation and lipid metabolism in preclinical studies, and its direct hepatic action was confirmed in a Phase 2a clinical study, further solidifying MetaVia's innovative position in the treatment of metabolic diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MTVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MTVA
Wall Street analysts forecast MTVA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.550
Low
40.00
Averages
47.50
High
55.00
Current: 1.550
Low
40.00
Averages
47.50
High
55.00
About MTVA
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
MetaVia to Participate in Life Sciences Investor Forum
- Executive Participation: MetaVia's CEO Hyung Heon Kim will participate in the Life Sciences Virtual Investor Forum on March 12, 2026, showcasing the company's innovative pipeline in obesity and metabolic therapies, which is expected to attract investor interest and enhance company visibility.
- Real-Time Interaction: The event will feature a live Q&A session, allowing investors to directly engage with management, thereby enhancing investor participation and fostering interaction between the company and potential investors, which may aid future fundraising efforts.
- Clinical Trial Progress: MetaVia's DA-1726 has demonstrated best-in-class potential for weight loss in a Phase 1 multiple ascending dose trial, indicating promising prospects for weight control and glucose management, potentially providing a competitive edge in the market.
- New Drug Development Results: Vanoglipel has shown positive effects on liver inflammation and lipid metabolism in preclinical studies, and its direct hepatic action was confirmed in a Phase 2a clinical study, further solidifying MetaVia's innovative position in the treatment of metabolic diseases.
See More
MetaVia to Participate in Life Sciences Investor Forum
- Executive Forum Participation: MetaVia's CEO Hyung Heon Kim will engage in a fireside chat at the Life Sciences Virtual Investor Forum on March 12, 2026, showcasing the company's pipeline in obesity and metabolic therapies, which is expected to attract investor interest and enhance company visibility.
- Innovative Therapy Development: MetaVia is developing DA-1726 for obesity treatment, which demonstrated best-in-class potential for weight loss and glucose control in a Phase 1 multiple ascending dose trial, potentially providing a significant competitive edge in the crowded biotech market.
- New Drug Research Progress: Vanoglipel (DA-1241), a novel GPR119 agonist, has shown positive effects on liver inflammation and lipid metabolism in preclinical studies, and its direct hepatic action was confirmed in a Phase 2a clinical study, further strengthening MetaVia's R&D capabilities.
- Investor Interaction Opportunities: The forum will feature a live Q&A session, allowing investors to participate through pre-registration, and MetaVia will also arrange one-on-one meetings to enhance engagement with investors, thereby increasing company transparency and investment appeal.
See More
MetaVia Announces Update on Obesity and Metabolic Therapies
- Conference Schedule: MetaVia Inc. will present an update on its novel obesity and metabolic therapies at the Emerging Growth Conference on February 25, 2026, at 10:15 AM ET, featuring insights from CEO Hyung Heon Kim and CFO Marshall H. Woodworth, showcasing the latest advancements in cardiometabolic disease treatments.
- DA-1726 Development Progress: The company’s DA-1726, a novel oxyntomodulin analogue acting as a dual agonist for GLP1R and GCGR, demonstrated best-in-class potential for weight loss, glucose control, and waist reduction in a Phase 1 multiple ascending dose trial, potentially outperforming selective GLP1R agonists.
- Clinical Effects of Vanoglipel: Vanoglipel, a novel GPR119 agonist, showed positive effects on liver inflammation, lipid metabolism, weight loss, and glucose metabolism in pre-clinical studies, effectively reducing hepatic steatosis, inflammation, and fibrosis while improving glucose control.
- Future Outlook: The promising results of MetaVia's new therapies in clinical trials position the company strategically for significant market opportunities in the treatment of cardiometabolic diseases, potentially enhancing its competitive edge in the biotechnology sector.
See More
MetaVia Announces Strong Global IP Portfolio Supporting DA-1726
- Intellectual Property Protection: MetaVia Inc. announced that its lead asset DA-1726 has secured 39 granted and pending patents in the U.S. and internationally, with patent protection extending to 2041, providing a solid foundation for the company's long-term strategy.
- Clinical Data Highlights: Recent clinical data revealed a promising 9% weight loss at the 48 mg dose of DA-1726, alongside significant improvements in waist size and blood sugar levels, indicating its potential in treating obesity and related metabolic disorders.
- Market Performance Analysis: Despite a staggering 90.85% decline in stock price over the past 12 months, the current RSI of 23.34 suggests the stock may be undervalued with rebound potential, trading at $1.84 near its 52-week low of $1.61.
- Analyst Rating Upgrade: HC Wainwright & Co. upgraded MetaVia's stock rating to 'Buy' with a target price raised to $40.00, reflecting confidence in its future growth potential, even as the overall healthcare sector shows lackluster performance.
See More
MetaVia Unveils Robust Intellectual Property Portfolio
- Intellectual Property Advantage: MetaVia Inc. currently holds 39 granted and pending patents covering both U.S. and international markets, providing protection until 2041, thereby ensuring the market competitiveness and commercialization potential of its core asset DA-1726.
- DA-1726 Clinical Data Highlights: At the 48 mg dose, DA-1726 demonstrated a significant weight loss of approximately 9%, waist circumference reduction, and improvements in blood sugar levels, indicating its best-in-class potential in treating obesity and metabolic diseases, further solidifying the company's position in the rapidly growing biotech sector.
- Clinical Trial Plans: MetaVia plans to conduct 16-week titration studies targeting doses of 48 mg and 64 mg, with results expected in Q4 2026, reflecting the company's confidence in DA-1726's tolerability and its potential advantages over existing GLP-1 treatments.
- Market Outlook: The patent protection and clinical data support MetaVia's long-term strategic development in the obesity and metabolic disease treatment space, which is expected to generate substantial market value and investment returns for the company.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
MetaVia to Participate in Life Sciences Investor Forum
- Executive Participation: MetaVia's CEO Hyung Heon Kim will participate in the Life Sciences Virtual Investor Forum on March 12, 2026, showcasing the company's innovative pipeline in obesity and metabolic therapies, which is expected to attract investor interest and enhance company visibility.
- Real-Time Interaction: The event will feature a live Q&A session, allowing investors to directly engage with management, thereby enhancing investor participation and fostering interaction between the company and potential investors, which may aid future fundraising efforts.
- Clinical Trial Progress: MetaVia's DA-1726 has demonstrated best-in-class potential for weight loss in a Phase 1 multiple ascending dose trial, indicating promising prospects for weight control and glucose management, potentially providing a competitive edge in the market.
- New Drug Development Results: Vanoglipel has shown positive effects on liver inflammation and lipid metabolism in preclinical studies, and its direct hepatic action was confirmed in a Phase 2a clinical study, further solidifying MetaVia's innovative position in the treatment of metabolic diseases.
See More
MetaVia to Participate in Life Sciences Investor Forum
- Executive Forum Participation: MetaVia's CEO Hyung Heon Kim will engage in a fireside chat at the Life Sciences Virtual Investor Forum on March 12, 2026, showcasing the company's pipeline in obesity and metabolic therapies, which is expected to attract investor interest and enhance company visibility.
- Innovative Therapy Development: MetaVia is developing DA-1726 for obesity treatment, which demonstrated best-in-class potential for weight loss and glucose control in a Phase 1 multiple ascending dose trial, potentially providing a significant competitive edge in the crowded biotech market.
- New Drug Research Progress: Vanoglipel (DA-1241), a novel GPR119 agonist, has shown positive effects on liver inflammation and lipid metabolism in preclinical studies, and its direct hepatic action was confirmed in a Phase 2a clinical study, further strengthening MetaVia's R&D capabilities.
- Investor Interaction Opportunities: The forum will feature a live Q&A session, allowing investors to participate through pre-registration, and MetaVia will also arrange one-on-one meetings to enhance engagement with investors, thereby increasing company transparency and investment appeal.
See More
MetaVia Announces Update on Obesity and Metabolic Therapies
- Conference Schedule: MetaVia Inc. will present an update on its novel obesity and metabolic therapies at the Emerging Growth Conference on February 25, 2026, at 10:15 AM ET, featuring insights from CEO Hyung Heon Kim and CFO Marshall H. Woodworth, showcasing the latest advancements in cardiometabolic disease treatments.
- DA-1726 Development Progress: The company’s DA-1726, a novel oxyntomodulin analogue acting as a dual agonist for GLP1R and GCGR, demonstrated best-in-class potential for weight loss, glucose control, and waist reduction in a Phase 1 multiple ascending dose trial, potentially outperforming selective GLP1R agonists.
- Clinical Effects of Vanoglipel: Vanoglipel, a novel GPR119 agonist, showed positive effects on liver inflammation, lipid metabolism, weight loss, and glucose metabolism in pre-clinical studies, effectively reducing hepatic steatosis, inflammation, and fibrosis while improving glucose control.
- Future Outlook: The promising results of MetaVia's new therapies in clinical trials position the company strategically for significant market opportunities in the treatment of cardiometabolic diseases, potentially enhancing its competitive edge in the biotechnology sector.
See More
MetaVia Announces Strong Global IP Portfolio Supporting DA-1726
- Intellectual Property Protection: MetaVia Inc. announced that its lead asset DA-1726 has secured 39 granted and pending patents in the U.S. and internationally, with patent protection extending to 2041, providing a solid foundation for the company's long-term strategy.
- Clinical Data Highlights: Recent clinical data revealed a promising 9% weight loss at the 48 mg dose of DA-1726, alongside significant improvements in waist size and blood sugar levels, indicating its potential in treating obesity and related metabolic disorders.
- Market Performance Analysis: Despite a staggering 90.85% decline in stock price over the past 12 months, the current RSI of 23.34 suggests the stock may be undervalued with rebound potential, trading at $1.84 near its 52-week low of $1.61.
- Analyst Rating Upgrade: HC Wainwright & Co. upgraded MetaVia's stock rating to 'Buy' with a target price raised to $40.00, reflecting confidence in its future growth potential, even as the overall healthcare sector shows lackluster performance.
See More
MetaVia Unveils Robust Intellectual Property Portfolio
- Intellectual Property Advantage: MetaVia Inc. currently holds 39 granted and pending patents covering both U.S. and international markets, providing protection until 2041, thereby ensuring the market competitiveness and commercialization potential of its core asset DA-1726.
- DA-1726 Clinical Data Highlights: At the 48 mg dose, DA-1726 demonstrated a significant weight loss of approximately 9%, waist circumference reduction, and improvements in blood sugar levels, indicating its best-in-class potential in treating obesity and metabolic diseases, further solidifying the company's position in the rapidly growing biotech sector.
- Clinical Trial Plans: MetaVia plans to conduct 16-week titration studies targeting doses of 48 mg and 64 mg, with results expected in Q4 2026, reflecting the company's confidence in DA-1726's tolerability and its potential advantages over existing GLP-1 treatments.
- Market Outlook: The patent protection and clinical data support MetaVia's long-term strategic development in the obesity and metabolic disease treatment space, which is expected to generate substantial market value and investment returns for the company.
See More
